Acer Therapeutics Inc. (ACER)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Acer Therapeutics Inc. (ACER) trades at $0.66 with AI Score 38/100 (Grade D). Acer Therapeutics Inc. is a pharmaceutical company focused on acquiring, developing, and commercializing therapies for serious rare and life-threatening diseases. Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for ACER: ACER does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ACER against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ACER: 1/1 perspectives are bearish.
How is this calculated? →Acer Therapeutics Inc. (ACER) Healthcare & Pipeline Overview
Acer Therapeutics Inc. is a biopharmaceutical company specializing in the development of treatments for rare and life-threatening diseases, focusing on clinical-stage assets like EDSIVO and ACER-001. With a lean structure and strategic collaborations, Acer aims to address unmet medical needs in niche therapeutic areas within the biotechnology sector.
What Is the Investment Thesis for ACER?
Acer Therapeutics presents a focused investment opportunity within the rare disease space. The company's value drivers include the potential approval and commercialization of EDSIVO for vEDS, a disease with limited treatment options. Positive clinical trial outcomes and regulatory approvals for ACER-001 in UCDs and MSUD could also significantly enhance shareholder value. The development of ACER-2820 as a host-directed therapy for infectious diseases provides further upside potential. However, the company faces risks related to clinical trial outcomes, regulatory hurdles, and the ability to secure funding for ongoing development programs. With a P/E ratio of -0.40 and a beta of 0.44, Acer demonstrates high risk and volatility. Successful execution of its clinical programs and strategic partnerships are critical for realizing its potential.
Based on FMP financials and quantitative analysis
ACER Key Highlights
- Acer Therapeutics focuses on therapies for rare and life-threatening diseases, a market with high unmet needs and potential for premium pricing.
- The company's pipeline includes four clinical-stage candidates, diversifying its risk and potential revenue streams.
- Acer has a research collaboration agreement with NCATS to develop emetine hydrochloride as a potential treatment for patients with COVID-19, showcasing innovation in infectious disease.
- A license agreement with Sanofi grants Acer worldwide rights to osanetant, expanding its portfolio with a clinical-stage asset.
- With 30 employees, Acer operates with a lean structure, potentially reducing operational costs.
Who Are ACER's Competitors?
ACER is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMHV American Hemp Ventures, Inc. | $0.98 | +0.00% | $16.47M | 46 |
| AXLA Axcella Health Inc. | $4.58 | +0.00% | $12.50M | 44 |
| ELEV ELEV | $0.36 | -2.12% | $21.63M | 47 |
| IMNN Imunon, Inc. | $2.03 | +6.28% | $5.12M | — |
| KA Kineta, Inc. | $0.57 | -30.77% | $7.05M | 45 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ACER's Key Strengths?
- Focus on rare diseases with high unmet needs.
- Pipeline of clinical-stage drug candidates.
- Strategic collaborations with research institutions and pharmaceutical companies.
- Lean operational structure.
What Are ACER's Weaknesses?
- Reliance on successful clinical trial outcomes.
- Dependence on regulatory approvals.
- Limited financial resources.
- Small team size.
What Could Drive ACER Stock Higher?
- Potential regulatory approval and commercial launch of EDSIVO for vascular Ehlers-Danlos Syndrome (vEDS).
- Clinical trial results for ACER-001 in Urea Cycle Disorders (UCDs) and Maple Syrup Urine Disease (MSUD).
- Progress in the development of ACER-2820 as a host-directed therapy for infectious diseases.
- Strategic partnerships and acquisitions to expand the company's pipeline.
- Advancements in drug development technologies to improve the efficiency and effectiveness of clinical trials.
What Are the Key Risks for ACER?
- Financial-distress signal — its Altman Z-Score of -29.87 sits in the distress zone (elevated bankruptcy risk).
- Insider selling — insiders were net sellers of roughly $14.6M recently.
- Clinical trial failures for key drug candidates.
- Regulatory setbacks and delays in obtaining approvals.
- Competition from larger pharmaceutical companies with greater resources.
- Dependence on securing funding to support clinical development programs.
- Patent expirations and loss of market exclusivity.
What Are the Growth Opportunities for ACER?
- EDSIVO for vascular Ehlers-Danlos Syndrome (vEDS): The market for vEDS treatments is largely untapped, with limited existing therapies. Successful clinical trials and regulatory approval for EDSIVO could establish Acer as a leader in this space. The potential market size is estimated to be significant, given the lack of effective treatments and the severity of the disease. Timeline for potential approval and commercialization is dependent on clinical trial outcomes and regulatory review, with potential launch within the next 2-3 years.
- ACER-001 for Urea Cycle Disorders (UCDs) and Maple Syrup Urine Disease (MSUD): ACER-001 offers a potentially improved formulation of sodium phenylbutyrate, addressing a known need in the treatment of UCDs and MSUD. The market for these metabolic disorders is established, with existing therapies providing a benchmark for pricing and market penetration. Positive clinical data and regulatory approval could allow ACER-001 to capture a significant share of this market. Timeline for potential approval and commercialization is dependent on clinical trial outcomes and regulatory review, with potential launch within the next 2-3 years.
- ACER-801 (osanetant) for induced Vasomotor Symptoms (iVMS): Acer acquired worldwide rights to osanetant from Sanofi, a clinical-stage asset targeting iVMS. This presents an opportunity to address a significant unmet need in women's health. The market for iVMS treatments is substantial, driven by the prevalence of menopause and the associated symptoms. Successful development and commercialization of osanetant could generate significant revenue for Acer. Timeline for potential approval and commercialization is dependent on clinical trial outcomes and regulatory review, with potential launch within the next 3-5 years.
- ACER-2820 (emetine) as a host-directed therapy for infectious diseases, including COVID-19: The collaboration with NCATS to develop emetine hydrochloride as a potential treatment for COVID-19 represents a significant growth opportunity. Host-directed therapies offer a novel approach to treating infectious diseases by targeting host cell mechanisms rather than the pathogen itself. The market for COVID-19 treatments remains substantial, and successful development of ACER-2820 could provide a valuable therapeutic option. Timeline for potential approval and commercialization is dependent on clinical trial outcomes and regulatory review, with potential launch within the next 2-4 years.
- Strategic Partnerships and Acquisitions: Acer's business model focuses on acquiring and developing promising clinical-stage assets. Continued success in identifying and securing strategic partnerships and acquisitions will be crucial for expanding its pipeline and driving long-term growth. The company's expertise in rare diseases and its lean operational structure position it well to capitalize on opportunities in the biotechnology sector. Timeline for potential partnerships and acquisitions is ongoing, with the company actively seeking new opportunities to expand its portfolio.
What Opportunities Does ACER Have?
- Expansion of pipeline through acquisitions and partnerships.
- Potential for orphan drug designation and market exclusivity.
- Growing awareness and demand for rare disease therapies.
- Advancements in drug development technologies.
What Threats Does ACER Face?
- Clinical trial failures.
- Regulatory setbacks.
- Competition from larger pharmaceutical companies.
- Patent expirations.
What Are ACER's Competitive Advantages?
- Focus on rare diseases provides market exclusivity and pricing power.
- Intellectual property protection through patents and regulatory exclusivity.
- Strategic partnerships with research institutions and pharmaceutical companies.
- Specialized expertise in developing therapies for rare diseases.
What Does ACER Do?
Acer Therapeutics Inc., founded in 1991 and headquartered in Newton, Massachusetts, is a pharmaceutical company dedicated to the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases, also known as orphan diseases. The company's strategy involves identifying and acquiring promising clinical-stage assets that have the potential to address significant unmet medical needs. Acer's pipeline currently features four clinical-stage product candidates: EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate, for the treatment of urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); ACER-801 (osanetant) for induced Vasomotor Symptoms (iVMS); and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. Acer collaborates with organizations like the National Center for Advancing Translational Sciences (NCATS) to advance its research and development efforts. The company also has a license agreement with Sanofi for worldwide rights to osanetant. Acer operates with a relatively small team of 30 employees, reflecting its focus on efficient development and strategic partnerships.
What Products and Services Does ACER Offer?
- Acquire therapies for rare and life-threatening diseases.
- Develop clinical-stage drug candidates.
- Focus on unmet medical needs in niche therapeutic areas.
- Seek regulatory approvals for their drug candidates.
- Commercialize approved therapies.
- Collaborate with research institutions and pharmaceutical companies.
How Does ACER Make Money?
- Acquire rights to promising drug candidates.
- Develop and conduct clinical trials to demonstrate efficacy and safety.
- Obtain regulatory approvals from agencies like the FDA.
- Commercialize approved drugs through partnerships or internal sales teams.
What Industry Does ACER Operate In?
Acer Therapeutics operates within the biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful products. The rare disease market is a growing segment within the biotechnology industry, driven by increasing awareness, regulatory incentives, and the potential for high drug prices. Competition comes from both large pharmaceutical companies and smaller biotech firms focused on developing therapies for specific rare diseases. Acer's success depends on its ability to navigate the complex regulatory landscape, secure funding for its clinical programs, and effectively commercialize its products.
Who Are ACER's Key Customers?
- Patients with rare and life-threatening diseases.
- Healthcare providers who treat these patients.
- Hospitals and clinics that administer the therapies.
- Payers, including insurance companies and government healthcare programs.
ROE 284%Key Financial Metrics
Return on equity for Acer Therapeutics Inc. stands at 283.9%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.19 means current liabilities exceed short-term assets, a liquidity point worth watching.
Acer Therapeutics Inc. (ACER) Valuation Context
Relative to its peer group, ACER's quantitative score of 38/100 is roughly in line with the peer average of 46/100.
Company Profile
Acer Therapeutics Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Newton, US. The company is led by CEO Christopher Schelling. ACER has traded publicly since 2004.
F-Score 4/9Financial Health
Acer Therapeutics Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -29.87 places it in the distress zone, a signal of elevated financial risk.
Net sellingInsider Activity
The most recent 12 insider filings for Acer Therapeutics Inc. break down as 6 sales and 6 purchases. On net that is roughly 3.3M shares disposed (about $14.6M), a signal worth weighing alongside the fundamentals.
ACER Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in ACER's pipeline, signaling potential positive developments.
- The community is buzzing about upcoming trial results, creating a wave of optimism around ACER's prospects.
- Positive sentiment in social trading circles indicates a belief in the company's long-term vision and strategic direction.
- Market perception suggests ACER is undervalued, with many seeing significant upside potential based on its current projects.
Bear Case
- Some insiders have recently reduced their positions, potentially indicating concerns about near-term performance.
- The community is expressing worries about potential delays in regulatory approvals, casting a shadow on immediate gains.
- Bearish views highlight the company's reliance on key pipeline assets, creating vulnerability if those assets falter.
- Market perception reflects skepticism about ACER's ability to successfully commercialize its products, leading to caution among investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ACER Latest News
No recent news available for ACER.
ACER Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ACER.
Price Targets
Wall Street price target analysis for ACER.
ACER MoonshotScore
What does this score mean?
The MoonshotScore rates ACER's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Christopher Schelling
CEO
Christopher Schelling serves as the Chief Executive Officer of Acer Therapeutics Inc. His background includes extensive experience in the pharmaceutical industry, with a focus on corporate strategy, business development, and commercialization. Prior to joining Acer, Schelling held leadership positions at various pharmaceutical companies, where he was responsible for driving growth and executing strategic initiatives. He brings a wealth of knowledge in drug development, regulatory affairs, and market access.
Track Record: Since assuming the role of CEO, Christopher Schelling has focused on advancing Acer's pipeline of clinical-stage drug candidates and securing strategic partnerships to support the company's growth. He has overseen the progress of EDSIVO and ACER-001 through clinical development and has been instrumental in securing collaborations with organizations like NCATS and Sanofi. His leadership has been critical in navigating the complex regulatory landscape and positioning Acer for future success.
What Investors Ask About Acer Therapeutics Inc. (ACER) — Healthcare
What does Acer Therapeutics Inc. do?
Acer Therapeutics Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes clinical-stage candidates targeting vascular Ehlers-Danlos Syndrome (vEDS), urea cycle disorders (UCDs), Maple Syrup Urine Disease (MSUD), induced Vasomotor Symptoms (iVMS), and infectious diseases like COVID-19. Acer's strategy involves identifying and acquiring promising assets, conducting clinical trials, and seeking regulatory approvals to bring these therapies to market, addressing unmet medical needs in niche therapeutic areas.
What are the main risks for ACER?
Acer Therapeutics faces several key risks inherent to the biotechnology industry. Clinical trial failures represent a significant risk, as negative results can halt the development of a drug candidate and significantly impact the company's valuation. Regulatory setbacks, such as delays in obtaining approvals or rejection of applications, can also negatively affect Acer's prospects. Competition from larger pharmaceutical companies with greater resources and established market presence poses a threat. Additionally, Acer is dependent on securing funding to support its clinical development programs, and any difficulty in raising capital could hinder its progress.
What are the key factors to evaluate for ACER?
Acer Therapeutics Inc. (ACER) holds an AI score of 38/100 (low). Not financial advice.
How frequently does ACER data refresh on this page?
ACER prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ACER's recent stock price performance?
Acer Therapeutics Inc. (ACER) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on rare diseases with high unmet needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ACER overvalued or undervalued right now?
Valuing Acer Therapeutics Inc. (ACER) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ACER?
Before investing in Acer Therapeutics Inc. (ACER), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding ACER to a portfolio?
Key strength of Acer Therapeutics Inc. (ACER): Focus on rare diseases with high unmet needs. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- AI analysis is pending and may provide further insights.
- Investment decisions should be based on individual risk tolerance and thorough research.